Taken together, our findings revealed that a subset of NPC patients may be amenable to biomarker-guided therapies targeting EGFR-PI3K-Akt-mTOR, NOTCH, NF-κB signaling and DNA repair pathways. The gene discussed is NFKB1; the disease is nasopharyngeal carcinoma.